Thermo Fisher Scientific (TMO) CEO says pharma reshoring is going to be a tailwind in 2027 and 2028 for this industry; will be active in deploying advanced AI capabilities to drive additional cost
Importance
Level 1
#THERMO FISHER SCIENTIFIC INC#TMO.US#EQUITIES#EU SESSION#US SESSION#LIFE SCIENCES TOOLS & SERVICES#LIFE SCIENCES TOOLS & SERVICES (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#TMO#US EQUITIES#AI